New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
18.12.2020 16:00:00 EET | Business Wire | Press release
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF’s expertise in virology, immunology and clinical investigation with Boehringer Ingelheim’s expertise in developing and manufacturing therapeutic antibodies, the partners developed BI 767551 as a potential new therapeutic and preventive/prophylactic option for fighting COVID-19.
Virus neutralizing antibodies are expected to become an important line of defense against SARS-CoV-2, complementing vaccines and nonpharmaceutical interventions. They are being investigated as a therapy option for individuals with mild or severe infections, but also as prevention or prophylaxis in non-infected people with a high risk of infection or at risk of serious outcomes. Directly delivering BI 767551 to the lung by inhalation has the potential to provide fast acting protection from virus infection in the respiratory tract.
The new antibody BI 767551 was derived from blood samples of recovered COVID-19 patients at UKK, examined for SARS-CoV-2 neutralization at UMR and developed further in collaboration with Boehringer Ingelheim. The clinical study will be led by Prof. Florian Klein and Prof. Gerd Fätkenheuer at UKK and Boehringer Ingelheim will supply the antibody. “With BI 767551, we aim to provide an effective option for preventing and treating COVID-19,” explains Prof. Florian Klein, Director of the Institute for Virology at the Cologne University Hospital and Principal Investigator at the DZIF.
”Monoclonal antibodies are a promising component in the fight against new viruses, such as the SARS-CoV-2. If this antibody turns out to be effective against COVID-19, this finding could be helpful in the current and also in future epidemics and pandemics. I am glad that we are able to assist in the development of this compound," says Prof. Stephan Becker, Director of the Institute of Virology at University of Marburg and Coordinator Emerging Infections, DZIF.
“We are excited to contribute to the development of BI 767551 in collaboration with our partners, with the aim to provide an innovative SARS-CoV-2 neutralizing antibody, combining a systemic with an inhaled route of administration” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit.
The Phase 1/2a studies (NCT04631705, NCT04631666) will evaluate the safety, pharmacokinetics and antiviral activity of the antibody. In Phase 1, the antibody will be administered to participants either with a single infusion or a single inhalation. If the antibody is well tolerated, late-stage confirmatory studies will be conducted.
Please click on the following link for ‘Notes to Editors’:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005318/en/
Contact information
Media Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com
Cologne University Hospital (UKK)
Christoph Wanko
Stellvertretender Pressesprecher
Stabsabteilung Unternehmenskommunikation
und Marketing
Tel.: +49 (221) 478 88757
christoph.wanko@uk-koeln.de
University of Marburg (UMR)
Dr. Gabriele Neumann
Leiterin der Stabsstelle Hochschulkommunikation
Pressesprecherin
Tel.: +49 6421 28-26118
Mail: gabriele.neumann@uni-marburg.de
German Center for Infection Research (DZIF)
Karola Neubert und Janna Schmidt
Pressestelle
Tel. : +49 6181 1170/1154
presse@dzif.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carrier and PHINIA Recognized with ISG Paragon Awards North America 2026 for Transformation Delivered with LTM30.9.2026 11:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that its clients PHINIA and Carrier have been recognized at the ISG Paragon Awards North America 2026. LTM received recognition in the Excellence category for its work with PHINIA and in the Transformation category for its work with Carrier. The ISG Paragon Awards recognize enterprise-provider partnerships that leverage technology, innovation, and new operating models to deliver measurable business impact. The recognitions highlight LTM's ability to help global enterprises accelerate transformation through industry expertise, technology innovation, and execution excellence. Carrier: Following significant M&A activities, Carrier, a global leader in intelligent climate and energy solutions, sought to address a fragmented technology landscape, siloed operating functions, and limited visibility into application ownership and costs across its 2,000+ application estate. LTM partnered closely with Carrier
RGI Expands Its Digital Insurance Proposition With the Acquisition of D4Next30.9.2026 11:00:00 EEST | Press release
RGI, the leading provider of digital solutions for the European insurance industry, announces the acquisition of D4Next, an insurance technology company specializing in solutions that connect insurance products, distribution channels and digital processes, powered by innovative AI models. The acquisition broadens RGI’s ability to support insurers in addressing one of the key challenges facing the industry: how to accelerate business and technological innovation while progressively evolving an increasingly complex technology landscape. Supporting the evolution of insurance at the pace of the market As insurers continue to invest in new products, digital channels, distribution models and more intelligent processes, the ability to introduce innovation progressively, and connect new capabilities with the technologies already supporting the business, is becoming increasingly important. With the acquisition of D4Next, RGI expands its proposition with capabilities designed to support this evo
Roquette to Showcase End-to-End Pharma Solutions for Patient-Centric Formulations at CPHI Milan 202630.9.2026 11:00:00 EEST | Press release
Roquette will showcase its end-to-end portfolio of pharmaceutical excipients, drug delivery solutions and leading technical expertise at CPHI Milan 2026 in Italy, where the company will welcome visitors at booth 1A18 in the excipients hall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929017969/en/ Visit Roquette at booth 1A18 in the excipients hall. At this year’s global industry event, Roquette will highlight key product brands supporting formulation performance, patient-centric drug delivery and biopharma innovation, including METHOCEL™ cellulose ethers, PEARLITOL® mannitol, Avicel® microcrystalline cellulose, POLYOX™ polyethylene oxide, KLEPTOSE® cyclodextrins, LYCADEX® pyrogen-free dextrose monohydrate, Qualicaps™ by Roquette hard capsules and its alginate portfolio from sustainably sourced seaweed. The company will also spotlight its biopharma solutions spanning upstream processing, downstream efficiency, and form
SoftBank Robotics Expands AI & Robotics Solutions for Foodservice in EMEA30.9.2026 10:30:00 EEST | Press release
SoftBank Robotics UK Ltd. today announced that it will showcase its AI & Robotics solutions for foodservice at EquipHotel 2026, taking place in Paris, France, from 2 to 5 November 2026, as part of its efforts to expand foodservice automation initiatives across the EMEA region. Hospitality and foodservice operators continue to face operational challenges, including labour shortages, difficulties in recruiting skilled staff, rising costs, inconsistent food quality, and food waste. SoftBank Robotics aims to help address these challenges through robotics and automation, supporting more efficient, consistent and flexible foodservice operations. STEAMA is a steam-based cooking robot that uses high-pressure, high-temperature steam to prepare frozen noodle dishes in about 90 seconds. Designed for simple, one-touch operation, it helps operators consistently serve freshly prepared dishes with ease. FLAMA and BOTINKIT Omni are automated cooking solutions that improve kitchen efficiency and consis
IFF Introduces AQUASCENT™: Advanced Water-Based Fragrance Technology30.9.2026 10:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances and health and biosciences, today introduced AQUASCENT™, a new vegan, water-based carrier for fine fragrance. Crafted from a proprietary formula made with biodegradable materials, AQUASCENT™ delivers enhanced olfactive performance and visual clarity for consumers while supporting a more sustainable approach to shipping the product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929938674/en/ AQUASCENT™ is IFF's new water-based fragrance carrier technology that maintains visual clarity while supporting fragrance loads from 10% to up to 25%, compared with up to 15% for most comparable systems. “AQUASCENT™ reflects our continued investment in new scent technologies and formats that create compelling fragrance experiences while supporting the industry’s growing focus on sustainability,” said Sabrya Meflah, president of Fine Fragrance for IFF Scent. “This technology illus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom